<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597257</url>
  </required_header>
  <id_info>
    <org_study_id>1720150047</org_study_id>
    <nct_id>NCT02597257</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain</brief_title>
  <official_title>Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain: Randomized, Controlled, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Food and Drug Safety, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conducted a randomized, Double blind, and Controlled Study to evaluate the
      Efficacy and safety of Lidocaine Infusion Treatment in Management of Neuropathic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators expect pain improvement after treatment with 3 mg/kg of lidocaine,
      continuously infused in normal saline 250 ml.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>11-point Numeric Rating Scale</measure>
    <time_frame>1 week after the end of intervention</time_frame>
    <description>Rating averaged daily pain score over a 7-day period, 0=on pain to 10=worst possible pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory Short Form</measure>
    <time_frame>at the end of intervention and 4 weeks after the end of intervention</time_frame>
    <description>measurements of pain intensity, functionality, and impact of pain, rated on an 11-point Numerical Rating Scale (NRS) [0=no pain to 10=worst possible pain]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shot Form McGill Pain Questionnaire</measure>
    <time_frame>at the end of intervention and 4 weeks after the end of intervention</time_frame>
    <description>15 pain descriptors ranked on a 4-stage intensity scale, the Present Pain Intensity index ranked on a 6-stage intensity and VAS (100-mm scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>at the end of intervention and 4 weeks after the end of intervention</time_frame>
    <description>7-point scale from very much improved to very much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with grade 3 through grade 5 adverse events that are related to study drug, graded according to NCI CTCAE version 4.0</measure>
    <time_frame>through the study completion (7 weeks)</time_frame>
    <description>AEs, laboratory values, vital signs, 12-lead ECG, finding from physical examination The intensity of AEs was graded according to the NCI common terminology criteria for adverse events v 4.0 on five point scale (grade 1 to 5: mild, moderate, severe, life-threatening and Death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11-point Numeric Rating Scale</measure>
    <time_frame>4 weeks after the end of intervention</time_frame>
    <description>Rating averaged daily pain score over a 7-day period, 0=on pain to 10=worst possible pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <condition>Diabetic Polyneuropathy</condition>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline
total 250 ml
once a week
4 times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lidocaine 3 mg/kg mixed in normal saline
total 250 ml
once a week
4 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine HCl</intervention_name>
    <description>lidocaine continuous infusion</description>
    <arm_group_label>Lidocaine HCl</arm_group_label>
    <other_name>183903BIJ, Lidocaine HCl inj. 2% DAEHAN PHARM. CO., LTD.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline continuous infusion</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>228714BIJ, ISOTONIC SODIUM CHLORIDE DAEHAN PHARM. CO., LTD.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postherpetic neuralgia, diabetic polyneuropathy, peripheral neuropathy

          -  NRS score &gt; 4

          -  stable oral medication during the 1 month trial period

          -  volunteers with informed consent

        Exclusion Criteria:

          -  pregnancy, breastfeeding, possibility of pregnancy

          -  pain from causes other than upper 3 indications

          -  hypersensitivity to lidocaine or other local anesthetics

          -  important disease of heart, kidney, liver or incurable disease that may affect the
             assessment of adverse effects, or may interfere with the completion of study

          -  severe conduction block

          -  history of other interventions that may affect the study

          -  Enrollment in other clinical trials within 30 days

          -  otherwise not suitable to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Chul Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Chul Kim</last_name>
    <phone>+82-2-2072-3289</phone>
    <email>pain@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yong Chul Kim</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Chul Kim, PhD</last_name>
      <phone>+82-2-2072-3289</phone>
      <email>pain@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jee Youn Moon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yong Chul Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lidocaine infusion therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

